Published in J Pharm Sci on September 23, 2011
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood (2012) 1.63
PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice. AAPS J (2011) 0.87
Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice. Cell Immunol (2015) 0.80
FVIII inhibitors: pathogenesis and avoidance. Blood (2015) 0.80
Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice. Biopharm Drug Dispos (2014) 0.79
Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice. J Pharm Sci (2014) 0.79
Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo. AAPS J (2014) 0.75
Violating the theory of single gene-single disorder: inhibitor development in hemophilia. Indian J Hematol Blood Transfus (2014) 0.75
Phosphorus assay in column chromatography. J Biol Chem (1959) 60.56
An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods (1999) 17.06
TGF-beta: a master of all T cell trades. Cell (2008) 4.60
Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol (2007) 4.29
Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol (2008) 2.50
Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther (2002) 2.33
Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res (1997) 1.91
Endocytosis and intracellular fate of liposomes using pyranine as a probe. Biochemistry (1990) 1.60
Minimizing the immunogenicity of protein therapeutics. Drug Discov Today (2004) 1.52
TGF-beta and regulatory T cell in immunity and autoimmunity. J Clin Immunol (2008) 1.49
Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care (1993) 1.26
Pharmacokinetic aspects of biotechnology products. J Pharm Sci (2004) 1.25
Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst (1989) 1.23
Phosphatidylserine regulates the maturation of human dendritic cells. J Immunol (2004) 1.20
Factor VIII structure and function. Thromb Haemost (1993) 1.14
Hemophilia A--from basic science to clinical practice. Semin Thromb Hemost (2002) 1.14
The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost (2009) 1.09
Factor VIII structure and function. Blood Rev (1989) 1.03
Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine (2004) 1.03
A role for thrombin in the initiation of the immune response to therapeutic factor VIII. Blood (2009) 0.97
Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice. AAPS J (2010) 0.97
Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells. J Thromb Haemost (2008) 0.97
Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice. Haemophilia (2010) 0.94
Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood (2001) 0.90
Immunobiology of inhibitor development in hemophilia A. Semin Thromb Hemost (2003) 0.89
Molecular characterization of the immune response to factor VIII. Vox Sang (2002) 0.89
Inhibition of DNA synthesis in peripheral blood mononuclear cells treated with phosphatidylserines containing unsaturated acyl chains. Immunopharmacology (1992) 0.87
Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation. Haematologica (2008) 0.84
Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. Haematologica (2000) 0.83
Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol (2007) 1.94
Delivery of therapeutic proteins. J Pharm Sci (2010) 1.58
A straightforward and highly efficient precipitation/on-pellet digestion procedure coupled with a long gradient nano-LC separation and Orbitrap mass spectrometry for label-free expression profiling of the swine heart mitochondrial proteome. J Proteome Res (2009) 1.46
Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T cells. J Immunol (2007) 1.33
Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS One (2011) 1.33
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. J Immunol (2008) 1.24
Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. J Pharm Sci (2008) 1.21
The 1.8 A crystal structure of PA2412, an MbtH-like protein from the pyoverdine cluster of Pseudomonas aeruginosa. J Biol Chem (2007) 1.13
Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res (2002) 1.11
IL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells. Clin Immunol (2005) 1.09
Utility of cleavable isotope-coded affinity-tagged reagents for quantification of low-copy proteins induced by methylprednisolone using liquid chromatography/tandem mass spectrometry. Anal Chem (2006) 1.05
Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res (2011) 1.04
Accurate localization and relative quantification of arginine methylation using nanoflow liquid chromatography coupled to electron transfer dissociation and orbitrap mass spectrometry. J Am Soc Mass Spectrom (2008) 1.03
Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clin Cancer Res (2005) 1.01
Quantification of Doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.99
Improved sensitivity for quantification of proteins using triply charged cleavable isotope-coded affinity tag peptides. Rapid Commun Mass Spectrom (2005) 0.99
Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice. AAPS J (2010) 0.97
Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-gamma, and eradicate tumor cells. J Immunol (2005) 0.95
Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS PharmSci (2003) 0.94
Pharmacodynamics and pharmacogenomics of diverse receptor-mediated effects of methylprednisolone in rats using microarray analysis. J Pharmacokinet Pharmacodyn (2002) 0.94
Phospholipid binding improves plasma survival of factor VIII. Thromb Haemost (2010) 0.92
T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets. Cancer Microenviron (2010) 0.91
Membrane-associated TGF-beta1 inhibits human memory T cell signaling in malignant and nonmalignant inflammatory microenvironments. J Immunol (2006) 0.91
Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems. AAPS J (2009) 0.90
Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma. J Immunol (2003) 0.90
Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function. Clin Immunol (2010) 0.90
Reciprocal functional modulation of the activation of T lymphocytes and fibroblasts derived from human solid tumors. J Immunol (2010) 0.89
IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments. Clin Immunol (2009) 0.89
Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics. Cancer Res (2012) 0.89
Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-κB and NFAT signaling in tumor-associated T cells. Cancer Immun (2013) 0.89
Tumor vaccination with cytokine-encapsulated microspheres. Methods Mol Med (2003) 0.88
Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice. J Pharm Sci (2009) 0.88
Mechanisms of tumor vascular priming by a nanoparticulate doxorubicin formulation. Pharm Res (2012) 0.87
PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice. AAPS J (2011) 0.87
Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells. Cancer Chemother Pharmacol (2013) 0.86
CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice. Cancer Immunol Immunother (2005) 0.86
Application of fluorescence spectroscopy to quantify shear-induced protein conformation change. Biophys J (2009) 0.86
Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A. J Pharm Sci (2008) 0.86
Transient cerebral hypoperfusion assisted intraarterial cationic liposome delivery to brain tissue. J Neurooncol (2014) 0.86
Germ line tumor-associated immunoglobulin VH region peptides provoke a tumor-specific immune response without altering the response potential of normal B cells. Blood (2004) 0.85
Exposure to factor VIII protein in the presence of phosphatidylserine induces hypo-responsiveness toward factor VIII challenge in hemophilia A mice. J Biol Chem (2013) 0.85
Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII. AAPS J (2009) 0.84
Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice. J Pharm Sci (2012) 0.84
In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting. Methods Mol Biol (2011) 0.84
Physiologically based pharmacokinetic models for everolimus and sorafenib in mice. Cancer Chemother Pharmacol (2013) 0.84
Memory T cells in human tumor and chronic inflammatory microenvironments: sleeping beauties re-awakened by a cytokine kiss. Immunol Invest (2006) 0.84
Human CD4+ effector T cells mediate indirect interleukin-12- and interferon-gamma-dependent suppression of autologous HLA-negative lung tumor xenografts in severe combined immunodeficient mice. Cancer Res (2002) 0.83
Immunogenicity of subcutaneously administered therapeutic proteins--a mechanistic perspective. AAPS J (2013) 0.82
Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model. Cancer Immun (2013) 0.82
Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. Pharm Res (2012) 0.81
Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacy. J Pharmacol Exp Ther (2012) 0.81
Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemother Pharmacol (2013) 0.81
Human nasal polyp microenvironment maintained in viable and functional states as xenografts in SCID mice. Ann Otol Rhinol Laryngol (2006) 0.81
Targeting the TCR signaling checkpoint: a therapeutic strategy to reactivate memory T cells in the tumor microenvironment. Expert Opin Ther Targets (2008) 0.81
Influence of route of administration and liposomal encapsulation on blood and lymph node exposure to the protein VEGF-C156S. J Pharm Sci (2011) 0.80
O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII. AAPS J (2007) 0.80
Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice. Biopharm Drug Dispos (2014) 0.79
Ultra-sensitive quantification of paclitaxel using selective solid-phase extraction in conjunction with reversed-phase capillary liquid chromatography/tandem mass spectrometry. J Chromatogr A (2008) 0.79
Cerebral hypoperfusion-assisted intra-arterial deposition of liposomes in normal and glioma-bearing rats. Neurosurgery (2015) 0.79
Cationic surface charge enhances early regional deposition of liposomes after intracarotid injection. J Neurooncol (2014) 0.79
Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice. J Pharm Sci (2014) 0.79
Use of a folding model and in situ spectroscopic techniques for rational formulation development and stability testing of monoclonal antibody therapeutics. J Pharm Sci (2010) 0.78
Interactions of everolimus and sorafenib in pancreatic cancer cells. AAPS J (2012) 0.78
Propofol, a general anesthetic, promotes the formation of fluid phase domains in model membranes. Chem Phys Lipids (2002) 0.78
Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib. J Pharm Sci (2012) 0.78
Phosphatidylinositol induces fluid phase formation and packing defects in phosphatidylcholine model membranes. Chem Phys Lipids (2011) 0.78
Memory T cells in the chronic inflammatory microenvironment of nasal polyposis are hyporesponsive to signaling through the T cell receptor. J Assoc Res Otolaryngol (2012) 0.78
Allometry of factor VIII and informed scaling of next-generation therapeutic proteins. J Pharm Sci (2013) 0.78
Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration. Biopharm Drug Dispos (2014) 0.78
Development and characterization of lipidic cochleate containing recombinant factor VIII. Biochim Biophys Acta (2007) 0.77
O-phospho-l-serine mediates hyporesponsiveness toward FVIII in hemophilia A-murine model by inducing tolerogenic properties in dendritic cells. J Pharm Sci (2014) 0.77
Noncovalent dimerization of paclitaxel in solution: evidence from electrospray ionization mass spectrometry. J Pharm Sci (2002) 0.77
Human nasal polyp microenvironments maintained in a viable and functional state as xenografts in NOD-scid IL2rgamma(null) mice. Ann Otol Rhinol Laryngol (2009) 0.77
B cell tumor vaccine enhanced by covalent attachment of immunoglobulin to surface proteins on dendritic cells. Clin Immunol (2005) 0.76
Folding considerations for therapeutic protein formulations. Prog Mol Biol Transl Sci (2008) 0.76
Interactions of everolimus and sorafenib in whole blood lymphocyte proliferation. Pharm Res (2012) 0.75
Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo. AAPS J (2014) 0.75
Immunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates. Drug Deliv (2010) 0.75
Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeutics. J Pharm Sci (2014) 0.75
Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model. J Pharmacol Exp Ther (2009) 0.75
Liposome-mediated cytokine gene delivery to human tumor xenografts. Methods Enzymol (2003) 0.75